EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Semaglutide in Practice: Insights from a Retrospective Case Series at a Jharkhand Tertiary Care Hospital

Ajay Kumar Jha, Ashok Sunder

Journal of The Association of Physicians of India · 2026-06 · 74 (6) · 74-77

DOI: 10.59556/japi.74.1508 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of The Association of Physicians of India, 2026-06. Verfasst von Ajay Kumar Jha und 1 weiteren Autor:innen. Beteiligte Einrichtung: Senior Consultant and Unit Head, Department of Medicine, Tata Main Hospital, Jamshedpur, Jharkhand, India, Corresponding Author. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated efficacy in improving glycemic control and reducing cardiovascular risk in patients with type 2 diabetes mellitus (T2DM). However, real-world evidence from Indian populations remains limited. This study aimed to assess the effectiveness and safety of semaglutide on glycemic control, body weight, and metabolic parameters in patients with T2DM in a real-world clinical setting. METHODS: -value 0.05). Thyroid function remained stable throughout the study period. Improvements in diabetic retinopathy and neuropathy were also observed, although these findings were not statistically significant. CONCLUSION: Semaglutide was effective and well tolerated in patients with T2DM in routine clinical practice. Treatment was associated with significant reductions in HbA1c, body weight, and LDL cholesterol without adverse effects on renal or thyroid function. These findings support the use of semaglutide as an effective therapeutic option for the management of T2DM in real-world settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsHumansSemaglutideFemaleMaleRetrospective StudiesIndiaGlycated HemoglobinTertiary Care CentersMiddle AgedBlood GlucoseBody WeightAgedTreatment Outcome

Substanzen

SemaglutideGlucagon-Like PeptidesHypoglycemic AgentsGlycated HemoglobinBlood Glucosehemoglobin A1c protein, human

Autor:innen und Institutionen

  • Senior Consultant and Unit Head, Department of Medicine, Tata Main Hospital, Jamshedpur, Jharkhand, India, Corresponding Author.
  • Chief Consultant, Department of Medicine, Tata Main Hospital, Jamshedpur, Jharkhand, India.

Zitieren

APA

Jha, A. K., & Sunder, A. (2026). Semaglutide in Practice: Insights from a Retrospective Case Series at a Jharkhand Tertiary Care Hospital. Journal of The Association of Physicians of India, 74(6), 74-77. https://doi.org/10.59556/japi.74.1508

Vancouver

Jha AK, Sunder A. Semaglutide in Practice: Insights from a Retrospective Case Series at a Jharkhand Tertiary Care Hospital. Journal of The Association of Physicians of India. 2026;74(6):74-77. doi:10.59556/japi.74.1508

BibTeX
@article{Jha2026,
  author = {Jha, Ajay Kumar and Sunder, Ashok},
  title = {Semaglutide in Practice: Insights from a Retrospective Case Series at a Jharkhand Tertiary Care Hospital},
  journal = {Journal of The Association of Physicians of India},
  year = {2026},
  volume = {74},
  number = {6},
  pages = {74--77},
  doi = {10.59556/japi.74.1508}
}
Kostenlos starten →